ClinicalTrials.gg
CompletedNCT02699580Updated Jan 25, 2017

Protective Effect of Biodegradable Collagen Implant (Ologen) in Scleral Thinning After Strabismus Surgery

An interventional study of lateral rectus recession with biodegradable collagen implant and Lateral rectus recession without biodegradable collagen implantation in Exotropia or Intermittent Exotropia, sponsored by Yonsei University. Completed at 1 site in Korea, Republic of. Open to participants aged 10 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-25.

Sponsored by Yonsei University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2015, registered Feb 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
10 Years to 70 Years
Sex
All
01

Study summary

This study is to investigate protective effect of biodegradable collagen implant in scleral showing after lateral rectus recession in patients with exotropia.

02

Conditions studied

  • Exotropia or Intermittent Exotropia

Browse trials for

Keywords

  • Biodegradable collagen implant
  • scleral thinning
  • strabismus surgery
03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's enrollment of 20 is below the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,418 studies on the registry; 241 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with intermittent exotropia or constant exotropia
  2. Alternate prism cover test showed 20 prism diopters or more than 20 prism diopters exotropia
  3. Subjects who want to do strabismus surgery

Exclusion criteria

Exclusion Criteria:

  1. Subject who had previous strabismus surgery or other ocular surgery history
  2. Thyroid eye disease or other connective tissue disease
  3. Significant bleeding or scleral perforation during operation
  4. Subjects who need to do medial rectus resection, not lateral rectus recession
  5. Subjects who had a plan to do other intra or extraocular surgery within 3 months
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Biodegradable collagen implant

    Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.

    Device: lateral rectus recession with biodegradable collagen implant

  • Active comparator
    Without biodegradable collagen implant

    Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.

    Procedure: Lateral rectus recession without biodegradable collagen implantation

Interventions

  • Devicelateral rectus recession with biodegradable collagen implant

    Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.

  • ProcedureLateral rectus recession without biodegradable collagen implantation

    Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.

06

What researchers measure

Primary outcomes

  1. Scleral thinning assessed with slit photography

    Scleral thinning at the area, where lateral rectus was originally inserted, was assessed with slit photography. Scleral thinning score was calculated from the Lab color model.

    Time frame: Postoperative 3 months

Secondary outcomes

  1. Ocular discharge assessed by questionnaire

    Ocular discharge will be assessed by questionnaire.

    Time frame: Postoperative 1 week

  2. Tearing assessed by questionnaire

    Tearing will be assessed by questionnaire.

    Time frame: Postoperative 1 week

  3. Foreign body sensation assessed by questionnaire

    Foreign body sensation will be assessed by questionnaire.

    Time frame: Postoperative 1 week

  4. Collagen implant protrusion assessed by questionnaire

    Collagen implant protrusion will be assessed by questionnaire.

    Time frame: Postoperative 1 week

07

Study locations

1 site
  • Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine
    Seoul, 03722, Korea, Republic of
08

References and documents

Publications

  • Pang Y, Gnanaraj L, Gayleard J, Han G, Hatt SR. Interventions for intermittent exotropia. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD003737. doi: 10.1002/14651858.CD003737.pub4. PubMed 34516656 ↗

Individual participant data

Plan to share: No — no plan to share individual participant data

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02699580
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Mar 4, 2016
Start date
Sep 30, 2015
Primary completion
Sep 10, 2016
Completion
Sep 10, 2016
Last update
Jan 25, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion